{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/30253"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/30253","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"PHARMACOLOGICAL COSTIMULATION OF ENGINEERED T CELLS","abstract":"Background: Chimeric antigen receptor (CAR) T cell therapy enlists genetic engineering to express a tumour targeting synthetic receptor on a patient’s T cells. While endogenous T cells rely on costimulatory signals for their development but not their effector function, CAR T cells are completely reliant on costimulatory domains incorporated within the CAR structure to promote T cell expansion and persistence in vivo, resulting in enhanced anti-tumour activity. Toxicities following CAR T cell infusion are linked to the magnitude and speed of the CAR T cell expansion, which is a function of signaling mediated through the costimulatory domain. Having a “druggable” method to provide costimulatory signals could be a strategy to: (i) tune in vivo T cell expansion, (ii) allow the physician to toggle costimulation during periods where it is advantageous to the therapeutic strategy, and (iii) enhance endogenous immune cell anti-tumour activity. A high throughput screen assessing 4000 biologically active compounds for their effect on engineered T cell proliferation identified Ferutinin, a natural small molecule with no known immunomodulatory activity. A small library of Ferutinin analogues (N=25) were synthesized to predict and optimize its biologically active molecular structure(s). Methods: We first assessed the impact of Ferutinin analogues on multiple classes of tumour re-targeting receptors TAC and DAP12 synthetic antigen receptor (SAR) engineered T cell function. We chose the TAC and DAP12 SAR receptor because they mediate T cell activation via natural signalling pathways and include no costimulatory domains. We then developed a high throughput screen (HTS) using luciferase as an indirect measure of TAC T cell number and screened >15,000 compounds with known biological activity at McMaster University’s Centre for Microbial and Chemical Biology. Finally, we validated the outcomes of the HTS. Results: Our studies did not find evidence of improved TAC or DAP12 SAR T cell function in the presence of Ferutinin analogues. The HTS did find classes of compounds with characterized costimulatory activity, including immunomodulatory drugs, phorbol esters and SMAC mimetics. 8- Geranyloxypsoralen and BAY 60 6583 demonstrated on-target enhancement of TAC T cell proliferation independent of T cell donor. Conclusions: These findings demonstrate the utility of small molecules as a method to enhance proliferation of engineered T cell products, recapitulating the effects of a costimulatory signal.","abstract_html":"Background: Chimeric antigen receptor (CAR) T cell therapy enlists genetic engineering to express a tumour targeting synthetic receptor on a patient’s T cells. While endogenous T cells rely on costimulatory signals for their development but not their effector function, CAR T cells are completely reliant on costimulatory domains incorporated within the CAR structure to promote T cell expansion and persistence in vivo, resulting in enhanced anti-tumour activity. Toxicities following CAR T cell infusion are linked to the magnitude and speed of the CAR T cell expansion, which is a function of signaling mediated through the costimulatory domain. Having a “druggable” method to provide costimulatory signals could be a strategy to: (i) tune in vivo T cell expansion, (ii) allow the physician to toggle costimulation during periods where it is advantageous to the therapeutic strategy, and (iii) enhance endogenous immune cell anti-tumour activity. A high throughput screen assessing 4000 biologically active compounds for their effect on engineered T cell proliferation identified Ferutinin, a natural small molecule with no known immunomodulatory activity. A small library of Ferutinin analogues (N=25) were synthesized to predict and optimize its biologically active molecular structure(s). Methods: We first assessed the impact of Ferutinin analogues on multiple classes of tumour re-targeting receptors TAC and DAP12 synthetic antigen receptor (SAR) engineered T cell function. We chose the TAC and DAP12 SAR receptor because they mediate T cell activation via natural signalling pathways and include no costimulatory domains. We then developed a high throughput screen (HTS) using luciferase as an indirect measure of TAC T cell number and screened &gt;15,000 compounds with known biological activity at McMaster University’s Centre for Microbial and Chemical Biology. Finally, we validated the outcomes of the HTS. Results: Our studies did not find evidence of improved TAC or DAP12 SAR T cell function in the presence of Ferutinin analogues. The HTS did find classes of compounds with characterized costimulatory activity, including immunomodulatory drugs, phorbol esters and SMAC mimetics. 8- Geranyloxypsoralen and BAY 60 6583 demonstrated on-target enhancement of TAC T cell proliferation independent of T cell donor. Conclusions: These findings demonstrate the utility of small molecules as a method to enhance proliferation of engineered T cell products, recapitulating the effects of a costimulatory signal.","abstract_has_math":false,"creators":["Adeel, Zoya"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Biochemistry and Biomedical Sciences","school":null,"contributors":[],"advisors":["Bramson, Jonathan"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-19T05:56:56Z","subjects":["Cancer","Small molecules","CAR-T","Genetic engineering"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/13843"],"render_values":[{"text":"https://doi.org/10.71548/13843","href":"https://doi.org/10.71548/13843","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/30253","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/30253","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F30253","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bramson, Jonathan"]},{"key":"dc:contributor.department","label":"Department","values":["Biochemistry and Biomedical Sciences"]},{"key":"dc:creator","label":"Author","values":["Adeel, Zoya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-09-30T14:00:53Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-09-30T14:00:53Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cancer","Small molecules","CAR-T","Genetic engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/30253","https://doi.org/10.71548/13843"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: Chimeric antigen receptor (CAR) T cell therapy enlists genetic engineering to express a tumour targeting synthetic receptor on a patient’s T cells. While endogenous T cells rely on costimulatory signals for their development but not their effector function, CAR T cells are completely reliant on costimulatory domains incorporated within the CAR structure to promote T cell expansion and persistence in vivo, resulting in enhanced anti-tumour activity. Toxicities following CAR T cell infusion are linked to the magnitude and speed of the CAR T cell expansion, which is a function of signaling mediated through the costimulatory domain. Having a “druggable” method to provide costimulatory signals could be a strategy to: (i) tune in vivo T cell expansion, (ii) allow the physician to toggle costimulation during periods where it is advantageous to the therapeutic strategy, and (iii) enhance endogenous immune cell anti-tumour activity. A high throughput screen assessing 4000 biologically active compounds for their effect on engineered T cell proliferation identified Ferutinin, a natural small molecule with no known immunomodulatory activity. A small library of Ferutinin analogues (N=25) were synthesized to predict and optimize its biologically active molecular structure(s). Methods: We first assessed the impact of Ferutinin analogues on multiple classes of tumour re-targeting receptors TAC and DAP12 synthetic antigen receptor (SAR) engineered T cell function. We chose the TAC and DAP12 SAR receptor because they mediate T cell activation via natural signalling pathways and include no costimulatory domains. We then developed a high throughput screen (HTS) using luciferase as an indirect measure of TAC T cell number and screened >15,000 compounds with known biological activity at McMaster University’s Centre for Microbial and Chemical Biology. Finally, we validated the outcomes of the HTS. Results: Our studies did not find evidence of improved TAC or DAP12 SAR T cell function in the presence of Ferutinin analogues. The HTS did find classes of compounds with characterized costimulatory activity, including immunomodulatory drugs, phorbol esters and SMAC mimetics. 8- Geranyloxypsoralen and BAY 60 6583 demonstrated on-target enhancement of TAC T cell proliferation independent of T cell donor. Conclusions: These findings demonstrate the utility of small molecules as a method to enhance proliferation of engineered T cell products, recapitulating the effects of a costimulatory signal."]},{"key":"dc:description.abstractgeneral","label":"General Abstract","values":["T cells protect the human body by surveilling and removing harmful cells. Scientific advancements have allowed us to re-target T cells to better eliminate cancer; this approach has demonstrated great clinical success for the treatment of blood cancers. Genetic modification strategies to enhance the clinical efficacy of existing re-targeted T cell products have been effective but are associated with toxicities. We propose using a chemical biology approach to enhance the function of modified T cells with small molecules, while potentially mitigating toxicities during treatment. We investigated over 15,000 chemicals compounds to identify candidate(s) that may improve genetically modified T cell function."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["PHARMACOLOGICAL COSTIMULATION OF ENGINEERED T CELLS"]},{"key":"dc:title.alternative","label":"Alternative Title","values":["Delivering Pharmacological Costimulation to Augment the Anti-tumour Activity of Engineered T cells"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bramson, Jonathan"],"dc:contributor.department":["Biochemistry and Biomedical Sciences"],"dc:creator":["Adeel, Zoya"],"dc:date.accessioned":["2024-09-30T14:00:53Z"],"dc:date.available":["2024-09-30T14:00:53Z"],"dc:date.issued":["2024"],"dc:description.abstract":["Background: Chimeric antigen receptor (CAR) T cell therapy enlists genetic engineering to express a tumour targeting synthetic receptor on a patient’s T cells. While endogenous T cells rely on costimulatory signals for their development but not their effector function, CAR T cells are completely reliant on costimulatory domains incorporated within the CAR structure to promote T cell expansion and persistence in vivo, resulting in enhanced anti-tumour activity. Toxicities following CAR T cell infusion are linked to the magnitude and speed of the CAR T cell expansion, which is a function of signaling mediated through the costimulatory domain. Having a “druggable” method to provide costimulatory signals could be a strategy to: (i) tune in vivo T cell expansion, (ii) allow the physician to toggle costimulation during periods where it is advantageous to the therapeutic strategy, and (iii) enhance endogenous immune cell anti-tumour activity. A high throughput screen assessing 4000 biologically active compounds for their effect on engineered T cell proliferation identified Ferutinin, a natural small molecule with no known immunomodulatory activity. A small library of Ferutinin analogues (N=25) were synthesized to predict and optimize its biologically active molecular structure(s). Methods: We first assessed the impact of Ferutinin analogues on multiple classes of tumour re-targeting receptors TAC and DAP12 synthetic antigen receptor (SAR) engineered T cell function. We chose the TAC and DAP12 SAR receptor because they mediate T cell activation via natural signalling pathways and include no costimulatory domains. We then developed a high throughput screen (HTS) using luciferase as an indirect measure of TAC T cell number and screened >15,000 compounds with known biological activity at McMaster University’s Centre for Microbial and Chemical Biology. Finally, we validated the outcomes of the HTS. Results: Our studies did not find evidence of improved TAC or DAP12 SAR T cell function in the presence of Ferutinin analogues. The HTS did find classes of compounds with characterized costimulatory activity, including immunomodulatory drugs, phorbol esters and SMAC mimetics. 8- Geranyloxypsoralen and BAY 60 6583 demonstrated on-target enhancement of TAC T cell proliferation independent of T cell donor. Conclusions: These findings demonstrate the utility of small molecules as a method to enhance proliferation of engineered T cell products, recapitulating the effects of a costimulatory signal."],"dc:description.abstractgeneral":["T cells protect the human body by surveilling and removing harmful cells. Scientific advancements have allowed us to re-target T cells to better eliminate cancer; this approach has demonstrated great clinical success for the treatment of blood cancers. Genetic modification strategies to enhance the clinical efficacy of existing re-targeted T cell products have been effective but are associated with toxicities. We propose using a chemical biology approach to enhance the function of modified T cells with small molecules, while potentially mitigating toxicities during treatment. We investigated over 15,000 chemicals compounds to identify candidate(s) that may improve genetically modified T cell function."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["http://hdl.handle.net/11375/30253","https://doi.org/10.71548/13843"],"dc:language.iso":["en"],"dc:subject":["Cancer","Small molecules","CAR-T","Genetic engineering"],"dc:title":["PHARMACOLOGICAL COSTIMULATION OF ENGINEERED T CELLS"],"dc:title.alternative":["Delivering Pharmacological Costimulation to Augment the Anti-tumour Activity of Engineered T cells"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-19T05:56:56Z"}